secwatch.observer — SEC 8-K summary
======================================

Issuer:     QuidelOrtho Corp (QDEL)
CIK:        0001906324
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001906324-23-000044
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QuidelOrtho Q2 revenue $665M, GAAP loss $(0.80)/share, adj. EPS $0.26; respiratory revenue down 74%
--------------------------------------------------------------------------------

- Revenue $665.1M (+8% reported) but down 26% on supplemental combined basis vs Q2 2022.
- GAAP diluted loss per share $(0.80); adjusted EPS $0.26 vs $2.12 supplemental combined prior year.
- Non-respiratory revenue +3% supplemental combined; Labs unit +9% constant currency; respiratory -74%.
- Paid down $72M on Term Loan (excess $20M) and final $40M for Alere Cardiometabolic acquisition.
- Completed Savanna EUA and 510(k) FDA submissions as planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1906324/000190632423000044/0001906324-23-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1906324/000190632423000044/qdel-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001906324-23-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer